Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction/aims: There are limited studies on the association of COVID-19 vaccination with neuralgic amyotrophy (NA). Therefore, we evaluated the association between COVID-19 vaccination and the occurrence of NA.
Methods: We explored unexpected safety signals for NA related to COVID-19 vaccination through disproportionality analysis using VigiBase, the World Health Organization's pharmacovigilance database.
Results: On October 15, 2021, 335 cases of NA were identified in the database. The median time to onset of NA after vaccination was around 2 weeks. A significant signal of disproportionality of NA was observed for the ChAdOx1 nCoV-19 vaccine (AstraZeneca) (information component [IC] = 0.33, reporting odds ratio [ROR] = 1.30) and two mRNA-based COVID-19 vaccines (BNT162b2 [Pfizer and BioNTech] and mRNA-1273 [Moderna]) (IC = 1.74, ROR = 3.82) compared with the entire database. However, when compared with influenza vaccines, we did not detect any signal of disproportionality of NA for both the ChAdOx1 nCoV-19 vaccine (IC = -2.71, ROR = 0.05) and mRNA-based COVID-19 vaccines (IC = -1.38, ROR = 0.13).
Discussion: A weak association was observed between NA and COVID-19 vaccines. However, the risk did not surpass that of influenza vaccines.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874732 | PMC |
| http://dx.doi.org/10.1002/mus.27734 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19.
Crit Rev Ther Drug Carrier Syst
January 2025
The emergence of messenger ribonucleic acid (mRNA) vaccines as an alternative platform to traditional vaccines has been accompanied by advances in nanobiotechnology, which have improved the stability and delivery of these vaccines through novel nanoparticles (NPs). Specifically, the development of NPs for mRNA delivery has facilitated the loading, protection and release of mRNA in the biological microenvironment, leading to the stimulation of mRNA translation for effective intervention strategies. Intriguingly, two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), have been permitted for emergency usage authorization to prevent COVID-19 infection by USFDA.
View Article and Find Full Text PDFDiscovery and mechanistic insights of dibenzoylmethane as a broad spectrum inhibitor of coronavirus.
PLoS Pathog
September 2025
State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Coronavirus, a large family of positive-sense RNA viruses, are responsible for both mild and severe respiratory illnesses, ranging from the common cold to life-threatening conditions. Despite significant advances in vaccine and antiviral development, the high mutability of human coronaviruses (HCoVs), such as SARS-CoV-2, presents a major challenge in treating these infections. Effective, broad-spectrum antiviral drugs are urgently needed to address both current and future HCoV outbreaks.
View Article and Find Full Text PDFserojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data.
PLoS Comput Biol
September 2025
Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Understanding acute infectious disease dynamics at individual and population levels is critical for informing public health preparedness and response. Serological assays, which measure a range of biomarkers relating to humoral immunity, can provide a valuable window into immune responses generated by past infections and vaccinations. However, traditional methods for interpreting serological data, such as binary seropositivity and seroconversion thresholds, often rely on heuristics that fail to account for individual variability in antibody kinetics and timing of infection, potentially leading to biased estimates of infection rates and post-exposure immune responses.
View Article and Find Full Text PDFPost COVID attitude, intent, awareness and preparedness of public to combat monkeypox infection in Odisha state, India.
J Infect Dev Ctries
August 2025
Department of Oral Radiology, College of Dentistry, Jouf University, Kingdom of Saudi Arabia.
Introduction: The coronavirus disease 2019 (COVID-19) pandemic highlighted the importance of public knowledge, vaccination, government preparedness, and a strong healthcare system in managing infectious diseases. Recently, monkeypox (mpox) cases have emerged globally. This study aimed to assess: (i) the public knowledge related to COVID-19 and its translation into preventive behavior, and (ii) the preparedness of the government and healthcare providers in addressing mpox.
View Article and Find Full Text PDFDevelopment of Receptor-Binding Domain (RBD)-Loaded PEG-PCL Nanoparticle Formulations Against SARS-CoV-2.
Macromol Biosci
September 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Tandogan, Ankara, Turkey.
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has highlighted the critical need for safe and effective vaccines. In this study, subunit nanovaccine formulations were developed using the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein encapsulated in polymeric nanoparticles composed of poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL). Two surfactants, poly(vinyl alcohol) (PVA) and sodium cholate (SC), were evaluated during formulation via a modified water-in-oil-in-water (w/o/w) emulsion-solvent evaporation method.
View Article and Find Full Text PDF